Accolade (NASDAQ:ACCD) released its quarterly earnings results on Wednesday. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.03, MarketWatch Earnings reports. The firm had revenue of $38.44 million for the quarter, compared to analyst estimates of $36.20 million. The business’s quarterly revenue was up 29.7% compared to the same quarter last year.
NASDAQ:ACCD opened at $49.67 on Friday. Accolade has a one year low of $28.68 and a one year high of $65.25. The firm’s fifty day moving average is $50.48.
A number of research firms have recently issued reports on ACCD. Zacks Investment Research lowered shares of Accolade from a “buy” rating to a “hold” rating in a report on Wednesday. Bank of America boosted their price objective on shares of Accolade from $45.00 to $51.00 and gave the company a “buy” rating in a research report on Thursday, October 15th. Canaccord Genuity initiated coverage on shares of Accolade in a research report on Tuesday, December 8th. They issued a “buy” rating and a $59.00 target price for the company. Piper Sandler boosted their target price on shares of Accolade from $55.00 to $57.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Credit Suisse Group boosted their target price on shares of Accolade from $42.00 to $45.00 and gave the stock a “neutral” rating in a research report on Friday. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Accolade presently has an average rating of “Buy” and a consensus target price of $50.08.
Accolade Company Profile
Accolade, Inc develops and provides technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and with multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists.
See Also: Does the Dogs of the Dow strategy work?
Receive News & Ratings for Accolade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accolade and related companies with MarketBeat.com's FREE daily email newsletter.